Business Wire

Teijin Receives Marketing Approval for Merz’s Xeomin ® Botulinum Toxin Type A in Japan

Share

Merz Pharmaceuticals GmbH, a leading neurotoxin company and subsidiary of Merz Pharma GmbH & Co. KGaA, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly announced today that Teijin Pharma has been granted approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity.

Xeomin® is effective in treating peripheral cholinergic nerve endings by weakening the contraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of a neurotransmitter called acetylcholine. The highly purified neurotoxin, the only active ingredient in Xeomin®, is made by removing complexing proteins from botulinum toxin type A, which is produced by Clostridium botulinum, using purification technology developed by Merz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin® to reduce the production of neutralizing antibodies capable of lowering efficacy.

Xeomin® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries to treat patients with upper limb spasticity, cervical dystonia, blepharospasm, or hypersalivation. Teijin Pharma signed an exclusive license and co-development agreement for Xeomin® in Japan with Merz Pharma GmbH & Co. KGaA in 2017. In August 2019, Teijin Pharma applied for marketing approval based on a significant improvement in the modified ashworth scale (MAS) score of the wrist flexion, which was observed in a phase-III clinical trial conducted by Merz in Japan.

Upper limb spasticity is a symptom of upper motor neuron syndrome, which is expressed mainly by increased muscle tone of upper limbs and the hyperexcitability of the stretch reflex as a sequela of stroke. The main symptoms are motor paralysis, hyperflexion, appearance of pathological reflexes, and sensory disturbances that complicate or impede activities in daily living.

Conventional treatment of upper limb spasticity includes physical rehabilitation and the use of oral muscle relaxants or neuromuscular blockers such as botulinum toxin type A. Injections of botulinum toxin type A are a Grade A recommendation in the Japanese Guidelines for the Management of Stroke 2015.

"At Merz Therapeutics, we do everything to bring better outcomes to more patients. Therefore, we are very proud of our partnership with Teijin to make Xeomin® available to physicians and patients in Japan,” said Stefan Brinkmann, CEO Merz Therapeutics. “We are confident that this treatment option can help patients with upper limb spasticity in Japan to experience more good days and achieve their unique goals.”

“Teijin Pharma already provides various pharmaceuticals and medical devices that help to contribute to improving quality of life of patients suffering from musculoskeletal diseases,” said Ichiro Watanabe, president of Teijin Pharma Limited. “We, responding to demographic change and increased health consciousness, are launching effective new drugs and providing other solutions to realize more sustainable societies. Teijin Pharma continues to contribute to improving the quality of life (QOL) of patients by providing new treatment options for diseases with high unmet needs.”

About Xeomin®

Brand name

Xeomin® 50 units for intramuscular injection

Xeomin®100 units for intramuscular injection

Xeomin® 200 units for intramuscular injection

Nonproprietary name

incobotulinumtoxinA

Dosage form

Injection (vial)

Indication

Upper limb spasticity

Dosage and administration

In general, for adults, Xeomin® should be injected into multiple tonic muscles.* The maximum dose per administration is 400 units, however, the dose should be appropriately reduced to the minimum depending on the type and number of targeted tonic muscles. Repeated doses are permissible if the effect of a previous dose diminish. The dosing interval should be 12 weeks or longer, but may be shortened to 10 weeks depending on the symptoms.

*Tonic muscles: flexor carpi radialis, flexor carpi ulnaris, flexor digitorum dorsi, flexor digitorum brevis, radial biceps, biceps brachii, brachial musculature, pronation of the pronator, flexor progenitor, flexor pollicis longus, adductor pollicis longus, flexor pollicis brevis/opposite thumb muscle, etc.

Xeomin® is the registered trademark of Merz Pharma GmbH & Co. KGaA.

About Merz Therapeutics

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated more than 110 years to developing innovations that meet patient and customer needs. Please visit www.merz.com.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields of environmental value; safety, security and disaster mitigation; and demographic change and increased health consciousness. Originally established as Japan's first rayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing three core business domains: high-performance materials including aramid, carbon fibers and composites, and also resin and plastic processing, films, polyester fibers and products converting; healthcare including pharmaceuticals and home healthcare equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT including B2B solutions for medical, corporate and public systems as well as packaged software and B2C online services for digital entertainment. Deeply committed to its stakeholders, as expressed in the brand statement “Human Chemistry, Human Solutions,” Teijin aims to be a company that supports the society of the future. The group comprises more than 170 companies and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD 9.4 billion) in the fiscal year that ended on March 31, 2020.

Please visit www.teijin.com

Contact information

Press Contact
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH
Global Communications
+49 69 1503 1265
Elisa.Antz@merz.de

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VentureIsrael Launches New Venture Capital Fund28.10.2020 01:08:00 CETPress release

VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech start-ups. The fund investment strategy focuses on the companies with clear-cut technological advantages, an experienced management team and a flexible business strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006270/en/ VentureIsrael Early Stage Deep Tech Fund (Graphic: Business Wire) The fund first investments are a secure quantum communications system, an AI market research solution and a next-generation correspondent banking platform. VentureIsrael is managed by five partners – all investment experts with diverse backgrounds: Michael Harte - former COO of Santander UK and Barclays; Roman Gold, Gadi Isaev and Alexander Zarankin of JSCapital – the Israeli investment platform; and Igor Turkin of Investment Management Group. “The Israeli innovation industry is demonstrating phenomenal

State-of-the-art Photography Results and Immersive AR Experiences: Infineon and pmd Offer 3D-imager With Longest Range in the Market27.10.2020 21:22:00 CETPress release

Gaming, virtual e-Commerce, 3D online education: Augmented Reality (AR) applications with three-dimensional depth sensors link the real with the digital world and are strongly demanded. Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) and pmdtechnologies developed a 3D depth sensor based on the Time of Flight (ToF)-technology which outperforms other solutions in the market and aims for target applications that offer a wider spectrum of innovative consumer usability. The 3D sensor market in smartphones for rear side cameras is expected to grow up to more than 500 million units per year until 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006197/en/ The new REAL3 ToF chip enables better photography results with a faster autofocus in low-light conditions or perfect night mode portraits based on picture segmentation. (Photo: Business Wire) “The latest 3D image sensor from Infineon and pmdtechnologies enables a new

IFF to Release Third Quarter 2020 Results November 927.10.2020 21:15:00 CETPress release

Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, announced that it will release its third quarter 2020 earnings results following the market close on Monday, November 9, 2020. The management team will host a live webcast on Tuesday, November 10, 2020 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, a

Panasonic: Verifiering av den hämmande effekten hos nanoe™ X, en teknik som nyttjar fördelarna med hydroxylradikaler, på det nya coronaviruset (SARS-CoV-2)27.10.2020 18:30:00 CETPressmeddelande

Panasonic tillkännagav idag, i samarbete med den globala kontraktforskningsorganisationen Texcell*1, att Texcell har verifierat den hämmande effekten hos nanoe™ X, en teknik som nyttjar fördelarna med hydroxylradikaler, på det det nya coronaviruset (SARS-CoV-2). nanoe™ X, en joniserare som genererar ”atomiserade vattenpartiklar av nanostorlek”, har utvecklas av Panasonic. Detta är en elektrostatisk atomiseringsteknik som samlar upp osynlig fukt i luften och tillför högspänning för att producera ”hydroxylradikaler i vattnet”. Den avgörande faktorn är att det förekommer hydroxylradikaler i nanoe™ X. Hydroxylradikalerna kännetecknas av att ha en hög oxidation och reaktivitet. Panasonic har bedrivit forskning på denna teknik sedan 1997 och har verifierat dess effektivitet på olika områden, inklusive hämning av vissa patogena mikroorganismer (bakterier, svampar och virus) och allergener, och att den bryter ned PM 2.5-komponenter som har negativa effekter på människokroppen*2. 2012 genomförd

VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART27.10.2020 17:40:00 CETPress release

Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, presents the target market for its active substance TOTUM-070, for untreated mild to moderate LDL-hypercholesterolemia. The Phase II clinical study has been initiated and will begin as soon as authorizations are received from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Committee for the Protection of Persons (CPP). TOTUM-070 is an innovative active substance derived from food plant extracts, without phytosterols nor red yeast rice, developed to act on lipid metabolism in individuals with hypercholesterolemia. Once development is complete, this new Health Nutrition product will be positioned mainly for people with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM-070 could be

Pulse Electronics Switches to Rimini Street Support for its SAP Applications27.10.2020 17:00:00 CETPress release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Pulse Electronics, a leading components manufacturer for the automotive and telecommunications industries, has switched to Rimini Street support for its SAP ECC 6.0 and Business Objects software. With the savings achieved by switching support providers, Pulse was able to divert its liberated funding to invest in business intelligence (BI) capabilities including artificial intelligence (AI) technologies to enable growth and competitive advantage during a year when new spending may not have otherwise been possible. The company was also able to defer an expensive forced migration to S/4HANA, required to remain in full support with the vendor, and instead has taken complete control of its IT roadmap to support the businesses’ objectives versus the vendor’s dictated roa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom